You are here: Profiles / Yvon D. Lapierre (List of Publications)
Tuesday, 12.12.2017

YVON D. LAPIERRE

LIST OF PUBLICATIONS

 

 

ORIGINAL PAPERS IN REFEREED JOURNALS

 

1.       LAPIERRE, Y, LAPOINTE, L, BORDELEAU, JM, TÉTREAULT, L

Phenothiazine treatment and electrocardiographic abnormalities: a survey of 106 psychiatric patients receiving thioridazine.  Can Psychiatr Assoc J 1969;14:517-23.

 

2.       LAPIERRE, Y, GAUTHIER, R, TÉTREAULT, L

Le couple fraternel hospitalisé : étude de la relation familiale. Laval Médical 1970;41:500-506.

 

3.       LAPIERRE, Y

Lithium intoxication. Can Psychiatr Assoc J 1972;17:106-12.

 

4.       LAPIERRE, Y, LAVALLÉE, J, TÉTREAULT, L

La mésoridazine chez les névrotiques : un essai clinique.  Union médicale Canada 1972;118:1509-12.

 

5.       LAPIERRE, Y

Koro in a French Canadian.  Can Psychiatr Assoc J 1972;17:4: 33334.

 

6.       LAPIERRE, Y, LAVALLEE, J, TÉTREAULT, L

Simultaneous mesoridazine and psychodrama treatment in neurotics.  Int J Clin Pharmacol 1973;7:1:62-65.

 

7.       LAPIERRE, Y, ELIE, R, TÉTREAULT, L

Diazepam & benzoctamine: effects on certain objective parameters of muscular spasticity. Curr Therap Res 1973; 15:521-33.

 

8.       DUSSAULT, A, LAPIERRE, Y

Étude démographique d'un secteur de psychiatrie communautaire.  Vie médicale Canada français 1973;2:881-86.

 

9.       LAVALLEE, J, LAPIERRE, Y

Psychodrame libre ou à thème induit.  Can Psychiatr Assoc J 1973;18:505-509.

 

10.    LAPIERRE, Y

The comparative anxiolytic effects of placebo, imipramine and clomipramine using psychiatric and psychophysiological measurements.  Int J Clin Pharmacol 1974;9:16-22.

 

11.    LAPIERRE, Y

Lithium en prophylaxie de la psychose maniaco-dépressive.  Une étude préliminaire de 21 cas.  Vie médicale Canada français 1974;3:282-87.

 

12.    LAPIERRE, Y

GSR and plethysmographic changes induced by clomipramine, imipramine and placebo.  Curr Therap Res 1974;16:461-69.

 

13.    LAPIERRE, Y, ELIE, R, TÉTREAULT, L

The antispastic effects of BA 34647 (B-4-chlorophenyl-aminobutyric acid) a GABA derivative.  Curr Therap Res 1974;16:1059-68.

 

14.    BÜTTER, HJ, LAPIERRE, Y

The effect of methylphenidate on sensory perception and integration in hyperactive children. Int Pharmacopsychiatry 1974;9:235-44.

 

15.    LAPIERRE, Y

Sédatifs hypnotiques et tranquillisants.  Vie médicale Canada français 1974;3:605-609.

 

 

16.    LAPIERRE, Y

Evaluation des effets secondaires chez les névrotiques : essai avec la mésoridazine et le placebo.  Can Psychiatr Assoc J 1975;20:61-66.

 

17.    LAPIERRE, Y

An assessment of the anxiolytic properties of clorazepate dipotassium, diazepam and placebo. J Pharmacol Clin 1975;1:41-45.

 

18.    LAPIERRE, Y

Clinical and physiological assessment of clorazepate, diazepam and placebo in anxious neurotics. Int J Clin Pharmacol & Biopharm 1975;11:315-22.

 

19.    BÜTTER, HJ, LAPIERRE, Y

The effect of methylphenidate on cardiovascular sensory differentiation in the hyperkinetic syndrome.  Int J Clin Pharmacol & Biopharm 1975;11:309-14.

 

20.    BÜTTER, HJ, LAPIERRE, Y

The effect of methylphenidate on sensory perception in varying degrees of hyperkinetic behaviour. Disord Nerv System 1975;36:286-88.

 

21.    LAPIERRE, Y

Pimozide and the social behaviour of schizophrenics.  Curr Therap Res 1975;18:181-88.

 

22.    RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Evidence for the role of brain biogenic amines in depressed locomotor activity seen in chemically thyroidectomized rats.  J Neurochem 1976;26:443-50.

 

23.    LAPIERRE, Y, LEE, M

Piperacetazine in the treatment of mixed neurotics.  Curr Therap Res 1976;19:1.

 

24.    GHADIRIAN, AM, LAPIERRE, Y

Recurrent post-operative psychotic reactions.  Mod Med Can 1976;31:15-18.

 

25.    LAPIERRE, Y

Control of lithium tremor with propranolol.  Can Med Assoc J 1976;114:619-20.

 

26.    LAPIERRE, Y, LAVALLEE, J

A controlled pimozide, fluphenazine & group psychotherapy study of chronic schizophrenics.  Psychiatr J Univ Ottawa 1976;1:1-2.

 

27.    RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Evidence for the role of brain norepinephrine and dopamine in "rebound" phenomenon seen during withdrawal after repeated exposure to benzodiazepines.  J Psychiatr Res 1976;13:65-75.

 

28.    RASTOGI, RB, AGARWAL, RA, LAPIERRE, Y, SINGHAL, RL

Effects of acute diazepam and clozabam on spontaneous locomotor activity and central amine metabolism in rats.  Eur J Pharmacol 1977;43:91-98.

 

29.    AGARWAL, RA, LAPIERRE, Y, RASTOGI, RB, SINGHAL, RL

Alterations in brain 5-hydroxytryptamine metabolism during the  "withdrawal" phase after chronic treatment with diazepam and bromazepam.  Br J Pharmacol 1977;60:3-9.

 

 

30.    BÜTTER, HJ, LAPIERRE, Y

Intersensory perception and integration in hyperkinetic children.  Psychiatr J Univ Ottawa 1977;11:78-83.

 

31.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Involvement of central noradrenergic system in the mediation of behavioral suppressant effects of diazepam in hyperthyroid rats.  Psychiatr J Univ Ottawa 1977;11:97-101.

 

32.    LAPIERRE, Y

Méthodes de mesures de l'anxiété en pharmacologie clinique.  Vie médicale Canada français 1978;7:362-68.

 

33.    KROGH, C, McLEAN, WM, LAPIERRE, Y

Minor tranquilizers in somatic disorders.  Can Med Assoc J 1978;118:1097-1108.

 

34.    RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Some neurochemical correlates of rebound phenomenon observed during withdrawal after long-term exposure to 1,4 benzodiazepines.  Prog Neuropsychopharmacol Biol Psychiatry 1978;2:43-54.

 

35.    LAPIERRE, Y, OYEWUMI, LK, GHADIRIAN, A

A placebo-controlled study of bromazepam and diazepam in anxiety neurosis.  Curr Therap Res 1978;23:4.

 

36.    LAPIERRE, Y

Assessment of long-acting neuroleptics: methods and problems. Int Pharmacopsychiat 1978;13:157-64.

 

37.    LAPIERRE, Y

Effectiveness of SCH 12679, a benzodiazepine in treatment of anxiety neurosis.  Curr Therap Res 1978;24:204-208.

 

38.    LAPIERRE, Y

A controlled study of penfluridol in the treatment of schizophrenia.  Am J Psychiatry 1978;135:956-59.

 

39.    LAPIERRE, Y, BÜTTER, HJ

Imipramine and maprotiline in agitated and retarded depression: a controlled psychiatric and psychophysical assessment.  Prog Neuropsychopharmacol Biol Psychiatry 1978;2:207-16.

 

40.    RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Effect of new benzodiazepine bromazepam on locomotor performance and brain monoamine metabolism.  J Neural Transm 1978;42:251-61.

 

41.    RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Synaptosomal uptake of norepinephrine and 5-hydroxytryptamine and synthesis of catecholamines during benzodiazepine treatment.  Can J Physiol Pharmacol 1978;56:777-84.

 

42.    RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Diazepam modifies L-triiodothyronine-stimulated changes in behaviour and the metabolism of brain norepinephrine, dopamine and 5-hydroxytryptamine: a possible mechanism of action. J Psychiatr Res 1979;15:7-20.

 

43.    LAPIERRE, Y, BERLISS, H, MONPREMIER, P, ELIE, R

Methodology and results of a long-term study of long-acting neuroleptics: pipotiazine palmitate and fluphenazine decanoate. Biol Psychiatry Today 1979B;1087-94.

 

44.    LAPIERRE, Y

Psychopharmacotherapy: a review of 20 years. Psychiatr J Univ Ottawa 1979;4:73-80.

 

 

45.    LAPIERRE, Y, GHADIRIAN, A, ST-LAURENT, J, CHAUDHRY, RP

Clozapine in acute schizophrenia: efficacy and toxicity.  Curr Therap Res 1980;27:391-400.

 

46.    LAPIERRE, Y, BÜTTER, HJ

Agitated and retarded depression: a clinical psychophysiological evaluation.  Neuropsychobiol 1980;6:217-23.

 

47.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Effects of rubidium & cesium on central catecholamines & locomotor behaviour in rats. J Neurochem 1980;34:1764-67.

 

48.    LAPIERRE, Y, GAGNON, A KOKKINIDIS, L

Rapid recurrence of mania following lithium withdrawal. Biol Psychiatry 1980;15:859-64.

 

49.    LAPIERRE, Y, SUSSMAN, P, GHADIRIAN, A

Differential antidepressant properties of trazodone and amitriptyline in agitated and retarded depression. Curr Therap Res 1980;28:845-56.

 

50.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Thyrotropin releasing hormone: neurochemical evidence for the potentiation of imipramine effects on the metabolism and uptake of brain catecholamines.  Psychopharmacol 1980;72:85-91.

 

51.    TELNER I, SINGHAL, RL, LAPIERRE, Y

Brain monoaminergic systems and inescapable shock: support for the learned helplessness hypothesis.  Neuroendocrinol Lett 1980;2:285-90.

 

52.    OYEWUMI, LK, LAPIERRE, Y

Efficacy of lithium in treating mood disorder after brain stem injury.  Am J Psychiatry 1981;138:110-12.

 

53.    MIDHA, KK, LAPIERRE, Y, HUBBARD, JW

Fluphenazine, trifluoperazine and perphenazine in vacutainers.  Can Med Assoc J 1981;124:263-64.

 

54.    HRDINA, PD, LAPIERRE, Y

Clinical response, plasma levels and pharmacokinetics of desipramine in depressed inpatients. Prog Neuropsychopharmacol Biol Psychiatry 1981;4.

 

55.    LAPIERRE, Y

Benzodiazepine withdrawal.  Can J Psychiatry 1981;26:93-95.

 

56.    SOLYOM, C, SOLYOM, L, LAPIERRE, Y, PECKNOLD, J, MORTON, L

Phenelzine and exposure in the treatment of phobias.  Biol Psychiatry 1981;16:239-47.

 

57.    COOPER, SF, LAPIERRE, Y

Gas/liquid chromatographic determination of pipotiazine in plasma of psychiatric patients. J Chromatog 1981;222:291-96.

 

58.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Effects of apomorphine on behavioral activity and brain catecholamine synthesis in normal and L-triiodothyronine-treated rats.  J Neural Transm 1981;50:139-48.

 

59.    MERALI, Z, LAPIERRE, Y

Prolactin and neuroleptic drug: a biochemical index of clinical response?  Int J Mental Health 1981;9:140-61.

 

 

 

60.    WATERS, BGH, LAPIERRE, Y

Secondary mania associated with sympathomimetic drug use.  Am J Psychiatry 1981;138:837-38.

 

61.    LAPIERRE, Y, RASTOGI, RB, SINGHAL, RL

Neurochemical changes produced by acute treatment with clozabam.  Gen Pharmacol 1981;12:261-66.

 

62.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Effects of short- and long-term neuroleptic treatment on brain serotonin synthesis and turnover: focus on the serotonin hypothesis of schizophrenia.  Life Sciences 1981;29:735-41.

 

63.    LAPIERRE, Y, OYEWUMI, LK, COLEMAN, B

The efficacy of fluvoxamine as an antidepressant.  Clin Trials J 1981;18:313-20.

 

64.    LAPIERRE, Y, CHAUDHRY, R, SIPOS, V

A long-term efficacy and toxicity study of fluspirilene in chronic schizophrenia. Curr Therap Res 1981;30:793-802.

 

65.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Thyrotropin releasing hormone potentiates the effects of imipramine on brain serotonergic system. Brain Res Bull 1981;7:449-51.

 

66.    RADONJIC, D, LAPIERRE, Y, KNOTT, V

The effect of methylphenidate on tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 1981;5:491-94.

 

67.    KNOTT, V, CHAUDHRY, R, LAPIERRE, Y

Panic induced by sodium lactate: electrophysiological correlates. Prog Neuropsychopharmacol Biol Psychiatry 1981;5:511-14.

 

68.    BOBON, DP, LAPIERRE, Y, LOTTIN, T

Validity and sensitivity of the French version of the Zerssen BFS/BFS' self-rating mood scale during treatment with trazodone and amitriptyline.  Prog Neuropsychopharmacol Biol Psychiatry 1981;5:519-22.

 

69.    TELNER, JI, SINGHAL, RL, LAPIERRE, Y

Reversal of learned helplessness by nortriptyline.  Prog Neuropsychopharmacol Biol Psychiatry 1981;5:587-90.

 

70.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Effects of MK-771, a novel TRH analog on brain dopaminergic and serotonergic systems. Eur J Pharmacol 1981;73:307-12.

 

71.    LAPIERRE, Y, OYEWUMI, KL

Fenobam: another anxiolytic? Curr Therap Res 1982;31:95-101.

 

72.    WATERS, BGH, LAPIERRE, Y

Therapeutic use of the tricyclic-induced switch in bipolar manic-depression. Am J Psychiatry 1982;139:245-46.

 

73.    RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Comparative effects of short- and long-term treatment with neuroleptics on behavioral activity as well as dopamine receptor in striatum.  Gen Pharmacol 1982;13:35-40.

 

74.    NAIR, NPV, SINGH, AN, LAPIERRE, Y, SAXENA, BM, NESTOROS, JN,  SCHWARTZ, G

Ketazolam in the treatment of anxiety: standard and placebo-controlled study. Curr Therap Res 1982;31:679-91.

 

 

 

75.    GELINAS, B, THORSTEINSON, L, LAPIERRE, Y

A placebo-controlled assessment of quazepam as a hypnotic. Curr Therap Res 1982;31:992-98.

 

76.    LAPIERRE, Y

A CFF assessment of clozabam and diazepam in anxiety neurosis. Pharmacopsychiatry 1982;15(Suppl 1):54-56.

 

77.    RASTOGI, SK, RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Effects of cholinergic & GABAergic drugs on apomorphine-induced gnawing behaviour in rats. Biol Psychiatry 1982;17:937-46.

 

78.    RASTOGI, RB, RASTOGI, SK, LAPIERRE, Y, SINGHAL, RL

Bromocriptine-induced changes in dopamine and gamma aminobutyric acid in haloperidol withdrawn rats. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:443-47.

 

79.    KNOTT, VJ, RADONJIC, D, LAPIERRE, Y

Cortical slow potential shifts in tardive dyskinesia.  Prog Neuropsychopharmacol Biol Psychiatry 1982;6:499-502.

 

80.    RASTOGI, SK, RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL

Effect of baclofen and haloperidol on Y-aminobutyric acid and dopamine systems in an animal model of tardive dyskinesia.  Gen Pharmacol 1982;13:499504.

 

81.    LAPIERRE, Y, TREMBLAY, A, GAGNON, A, MONPREMIER, P, BERLISS, H, OYEWUMI, LK

A therapeutic and discontinuation study of clozabam and diazepam in anxiety neurosis.  J Clin Psychiatry 1982;43:372-74.

 

82.    WATERS, B, LAPIERRE, Y, GAGNON, A, CHAUDHRY, R, TREMBLAY, A, SARANTIDIS, D, GRAY, R

Determination of the optimal concentration of lithium for the prophylaxis of manic-depressive disorder.  Biol Psychiatry 1982;17:1323-29.

 

83.    WATERS, BG, LAPIERRE, Y

Current psychopharmacogenetic strategies in primary affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:675-79.

 

84.    HRDINA, PD, HUTCHINSON, LJ, LAPIERRE, Y, PEREL, JM, REED, KL

Pharmacokinetics of psychotropic drugs: what can it tell us? Prog Neuropsychopharmacol Biol Psychiatry 1982;6:681-88.

 

85.  LAPIERRE Y.D.

          Neurotransmitter functions in depression. Prog.Neuro.Psychopharmacol.& Biol. Psychiatr. 1982,6(4-6):639-644.

 

86.    LAPIERRE, Y, ANDERSON, L

Dyskinesia associated with amoxapine antidepressant therapy: a case report.  Am J Psychiatry 1983;140:493-94.

 

87.    HRDINA, PD, LAPIERRE, Y, McINTOSH, B, OYEWUMI, LK

Mianserin kinetics in depressed patients.  Clin Pharmacol Ther 1983;33:757-62.

 

88.    RASTOGI, SK, RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Behavioral and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.  Prog Neuropsychopharmacol Biol Psychiatry 1983;7:153-64.

 

89.    LAPIERRE, Y, VON FRENCKELL, R

AMPD psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics. Mod Prob Pharmacopsychiatry 1983;20:193-203.

 

90.    LAPIERRE, Y, BÜTTER, HJ, OYEWUMI, LK

Benzodiazepine effect on information processing in GAD.  Neuropsychobiol 1983;9:88-93.

 

91.    WATERS, B, THAKAR, J, LAPIERRE, Y

Erythrocyte lithium efflux variables as marker for manic-depressive disorder. Neuropsychobiol 1983;9:94-98.

 

92.    BÜTTER, HJ, LAPIERRE, Y, FIRESTONE, P, BLANK, A

A comparative study of the efficacy of ACTH4-9 analog, methylphenidate, and placebo on attention deficit disorder with hyperkinesis.  J Clin Psychopharm 1983;3:226-30.

 

93.    RASTOGI, SK, RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

SL76002: effect on gamma-aminobutyric acid and dopamine in animals treated chronically with haloperidol.  Neuropsychobiol 1983;9:211-14.

 

94.    OYEWUMI, KL, LAPIERRE, Y, GRAY, R, BATTH, S, GELFAND, R

Abnormal involuntary movements in patients on long-acting neuroleptics. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:719-23.

 

95.    OYEWUMI, KL, LAPIERRE, Y, HRDINA, PD

Clinical effects of mianserin in endogenous depression and their relationship to drug plasma level. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:733-38.

 

96.    LAPIERRE, Y, OYEWUMI, KL

Suriclone: a new anxiolytic drug. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:805-807.

 

97.    SINGHAL, RL, RASTOGI, RB, LAPIERRE, Y

Diazepam potentiates the effect of neuroleptics on behavioral activity as well as dopamine and norepinephrine turnover: do benzodiazepines have antipsychotic potency? J Neural Transm 1983;56:127-38.

 

98.    LAPIERRE, Y, BULMER, DR, OYEWUMI, LK, MAUGUIN, ML, KNOTT, VJ

Comparison of chlormethiazole (heminevrin) and chlordiazepoxide (librium) in the treatment of acute alcohol withdrawal.  Neuropsychobiol 1983;10:127-30.

 

99.    LAPIERRE, Y, RASTOGI, RB, SINGHAL, RL

Fluvoxamine influences serotonergic system in the brain: neurochemical evidence. Neuropsychobiol 1983;10:213-16.

 

100.  LAPIERRE, Y

New concepts in the management of depressive illness.  Acta Psychiatr Scand 1983;68(suppl 308):167-70.

 

101. LAPIERRE, Y

Are all benzodiazepines clinically equivalent? Prog Neuropsychopharmacol Biol Psychiatry 1983;7:641-46.

 

102.  LAPIERRE, Y:

New antidepressant drugs. J Clin Psychiatry 1983;44:41-44.

 

103.  LAPIERRE, Y, KNOTT, VJ, GRAY, R

Psychophysiological correlates of sodium lactate. Psychopharmacol Bull 1984;20:50-57.

 

104.  KNOTT, VJ, WATERS, B, LAPIERRE, Y, GRAY, R

Neurophysiological correlates of sibling pairs discordant for bipolar affective disorder. Am J Psychiatry 1985;142:2.

 

105.  THAKAR, JH, LAPIERRE, Y, WATERS, BG

Erythrocyte membrane sodium potassium and magnesium atpase in primary affective disorder. Biol Psychiatry 1985;20:734-40.

 

106.  HRDINA, PD, LAPIERRE, Y KORANYI, EK

Altered amitriptyline kinetics in depressed patient with porto-caval anastomosis. Can J Psychiatry 1985;30:111-13.

 

107.  THAKAR, JH, LAPIERRE, Y, WATERS, BG

Cholinesterase in primary affective disorders.  Clin Biochem 1985;18:308-10.

 

108.  GELINAS, B, THORSTEINSON, L, LAPIERRE, Y

Zopiclone in the treatment of insomniacs of family practice.  Psychiatr J Univ Ottawa 1985;10:165-68.

 

109.  RASTOGI, SK, RASTOGI, RB, SINGHAL, RL, LAPIERRE, Y

Role of cholinergic system in modulating gamma-aminobutyric acid and dopamine functions in rats. Drug Devel Res 1985;6:47-54.

 

110.  HRDINA, PD, LAPIERRE, Y, HORN, E, BAKISH, D

Platelet 3H imipramine binding: a possible predictor of response to antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:619-23.

 

111.  LAPIERRE, Y

Course of clinical response to antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1985;9:503-507.

 

112.  BAKISH, D, LAPIERRE, Y

Disulfiram and bipolar affective disorder: case report.  J Clin Psychopharm 1986;6:178-79.

 

113.  BAKISH, D, LAPIERRE, Y

Myalgia with the new generation antidepressants.  J Clin Psychopharm 1986;6:195-96.

 

114.  TELNER, J, LAPIERRE, Y, HORN, E, BROWNE, M

Rapid reduction of mania by reserpine.  Am J Psychiatry 1986;143:1058.

 

115.  COLE, W, LAPIERRE, Y

The use of tryptophan in normal-weight bulimia.  Can J Psychiatry 1986;31:755-56.

 

116.  KNOTT, VJ, LAPIERRE, Y

Effects of lactate-induced panic attacks on brain stem auditory evoked potentials. Neuropsychobiol 1986;16:9-14.

 

117.  HORN, E, HRDINA, PD, LAPIERRE, Y

Nomifensine overdose with TCAs and MAOIs.  J Clin Psychopharm 1986;6:315-16.

 

117HRDINA, PD, LAPIERRE, Y

Plasma levels of maprotiline and zimeldine and their relationship to clinical response in depressed patients.  Ther Drug Monit 1986;8:400-406.

 

118.  LAPIERRE, Y, HRDINA, PD

Noo-analeptiques.  Semaine de l'hôpital de Paris 1986;62:1353-60.

 

119.  LAPIERRE, Y

Benzodiazepines.  Med N Am 1986;37:5398-5411.

 

120.  LAPIERRE, Y

Psychopharmacology in the classification of the schizophrenias:  from ICD-9 to DSM-III.  J Psychiat Biol Ther 1986;23:11-15.

 

 

121.  LAPIERRE, Y, BROWNE, M, HORN, E, OYEWUMI, L, SARANTIDIS, D, et al.

Treatment of major affective disorder with fluvoxamine.  J Clin Psychiatry 1987;48:65-68.

 

122.  KNOTT, VJ, LAPIERRE, Y

Electrophysiological and behavioral correlates of psychomotor responsivity in depression. Biol Psychiatry 1987;22:313-24.

 

123.  FRASER, GA, LAPIERRE, Y

The effect of buspirone on panic disorder: case report.  J Clin Psychopharm 1987;7:118-19.

 

124.  LAPIERRE, Y

Clinical and biological correlates of panic states.  Prog Neuropsychopharmacol Biol Psychiatry 1987;11:91-96.

 

125.  LAPIERRE, Y, LABELLE, A

Manic-like reaction induced by lorazepam withdrawal: case report.  Can J Psychiatry 1987;32:697-98.

 

126.  RUIZ, I, MATSOS, GL, WESTIN, J-A, LUNDBERG, G, TAYLOR, W, LAPIERRE, Y

Multi-systemic reactions to zimelidine in Canada: premarketing assessment using the adverse reactions probability scale. Curr Ther Res 1987;42.

 

127.  LAPIERRE, Y

Nouvelles règles des essais thérapeutiques en psychiatrie.  Psychol médicale 1987;19:2101-2104.

 

128.  KNOTT, VJ, LAPIERRE, Y

Computerized EEG correlates of depression and antidepressant treatment.  Prog Neuropsychopharmacol Biol Psychiatry 1987;11:213-21.

 

129.  LAPIERRE, Y et al.

Treatment of major affective disorder with fluvoxamine.  J Clin Psychiatry 1987;48:65-68.

 

130.  HRDINA, PD, LAPIERRE, Y, HORN, E, BAKISH, D, BROWNE, M

Antidepressant plasma levels and clinical response in depressed patients treated with oxaprotiline and doxepin. Int Clin Psychopharm 1988;3:205-14.

 

131.  HORN, E, LACK B, LAPIERRE, Y, HRDINA, P

Hypothalamic pathology in the neuroleptic malignant syndrome.  Am J Psychiatry 1988;145:617-20.

 

132.  KNOTT, V, LAPIERRE, Y

Neuropsychophysiological correlates of lactate-induced panic.  Prog Neuropsychopharmacol Biol Psychiatry 1988;12:183-92.

 

133.  TELNER, J, SURPHLIS, W, LAPIERRE, Y, MEHTA, G

Effects of antidepressants on thinking styles in depressed inpatients. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:277-84.

 

134.  WATERS, B, SENGAR, D, MARCHENKO, I, ROCK, G, LAPIERRE, Y, FORSTER-GIBSON, C, SIMPSON, N

A linkage study of primary affective disorder.  Br J Psychiatry 1988;152:560-61.

 

135.  LAPIERRE, Y

Trimipramine, 30 years of clinical use. Proceedings of Depression, Sleep Disorders and Trimipramine Symposium. (Adis Press) Limited Drugs 1989;38(suppl 1):17-24.

 

 

136.  BOURIN, MS, KERGUERIS, MF, LAPIERRE, Y

Therapeutic monitoring of treatment with antidepressants.  Psychiatr J Univ Ottawa 1989;14:460-62.

 

137.  SIGNER, SF, LAPIERRE, Y

Photophobia in depression (letter).  Am J Psychiatry 1989;146:1344-46.

 

138.  HRDINA, PD, BAKISH, D, SWENSON, S, LAPIERRE, Y

Cis- and trans-isomers of doxepin and desmethyldoxepin in plasma of depressed patients treated with doxepin.  Ther Drug Monit 1989;12:129-33.

 

139.  JOSTELL, K-G, LAPIERRE, Y, & The Canadian Remoxipride Study Group.

Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. Acta Psychiatr Scand 1990; 82(suppl 358):48-50.

 

140.  LAPIERRE, Y, NAIR, NPV, CHOUINARD, G, et al.

A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia: a Canadian multicentre trial.  Acta Psychiatr Scand 1990;82 (suppl 358):72-76.

 

141.  BROWNE, M, LAPIERRE, Y, HRDINA, PD, HORN, E

Lithium as an adjunct in the treatment of major depression.  Int Clin Psychopharm 1990;5:103-10.

 

142.  AWAD, A, LAPIERRE, Y, JOSTELL, K & The Canadian Remoxipride Study Group

Selective dopamine D2 antagonist and prolactin response in acute schizophrenia: results from remoxipride studies.  Prog Neuropsychopharmacol Biol Psychiatry 1990;14:769-77.

 

143.  HRDINA, P, BAKISH, D, SWENSON, S, LAPIERRE, Y

Prediction of steady-state plasma levels of doxepin and imipramine from single dose levels in depressed outpatients. J Psychiatry Neurosci 1991;16:25-29.

 

144.  REIMHERR, F, CHOUINARD, G, COHN, C, COLE, JO, ITIL, T, LAPIERRE, Y, ASCO, H, MENDELS, J

Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.  J Clin Psychiatry 1990;51(12 suppl B):18-27.

 

145.  KNOTT, V, LAPIERRE, Y

Temporal segmentation of response speed in depression: neuroelectrophysiological approaches.  Prog Neuropsychopharmacol Biol Psychiatry 1991;15:249-55.

 

146.  KNOTT, V, LAPIERRE, Y, DELUGT, D, GRIFFITHS, L, BAKISH, D, BROWNE, M, HORN, E

Preparatory brain potentials in major depressive disorder.  Prog Neuropsychopharmacol Biol Psychiatry 1991;15:257-62.

 

147.  KNOTT, V, LAPIERRE, Y, GRIFFITHS, L, DELUGT, D, BAKISH, D

Event-related potentials and selective attention in major depressive illness. J Affect Disord 1991;23:43-48.

 

148.  KNOTT, V, LAPIERRE, Y, FRASER, G, JOHNSON, N

Auditory evoked potentials in panic disorder. J Psychiatry Neurosci 1991;16:215-20.

 

149.  LABELLE, A, LAPIERRE, Y

Keratoderma: side effects with lithium. J Clin Psychopharm 1991;11:149-50.

 

150.  LAPIERRE, Y

Controlling acute episodes of depression. Int Clin Psychopharm 1991;6(suppl 2):23-25.

 

 

151.  LAPIERRE, Y

New perspectives in the treatment of depression. Can J Psychiatry 1992;37(suppl 1):3.

 

152.  WIENS, A, BAKISH, D, ELLIS, J, LAPIERRE, Y

A double-blind placebo-controlled comparison of moclobemide and amitriptyline in the treatment of depression.  Can J Psychiatry 1992;37(suppl 1):12-17.

 

153.  LAPIERRE, Y, ANCILL, R, AWAD, G, BAKISH, D, BEAUDRY, P, BLOOM, D, CHANDRASENA, R, DAS, M, DURAND, C, ELLIOTT, D, HORN, E, JONES, B, MANCHANDA, R, MAX, P, McCLURE, D, RAVINDRAN, A, ROTSTEIN, E, SANDOR, P, SAXENA, B, SLADEN-DEW, N

A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatry Neurosci 1992;17:135-45.

 

154.  FILTEAU, MJ, LAPIERRE, Y, BAKISH, D, BLANCHARD, D

Reduction in suicidal ideation with SSRIs: a review of 459 depressed patients. J Psychiatry  Neurosci 1993;18:114-19.

 

155.  LAPIERRE, Y, LABELLE, A

Anxiety disorders: diagnosis and treatment. Can Fam Physician 1993;39:2194-2201.

 

156.  LABELLE, A, LAPIERRE, Y

Anxiety disorders: pharmacotherapy with benzodiazepines. Can Fam Physician 1993;39:2205-13.

 

157.  LAPIERRE, Y, RAVINDRAN, AV, BAKISH, D

Dysthymia and serotonin. Int Clin Psychopharm 1993;8(suppl 2):87-90.

 

158.  LAPIERRE, Y

The multiplicity of uses of benzodiazepines. Can J Psychiatry 1993;38(suppl 4):S101.

 

159.  BAKISH, D, LAPIERRE, Y, WEINSTEIN, R, KLEIN, J, WIENS, A, JONES, B, HORN, E, BROWNE, M, BOURGET, D, BLANCHARD, A, THIBODEAU, C, WADDELL, C, RAINE, D

Ritanserin, imipramine & placebo in the treatment of dysthymic disorder. J Clin Psychopharm 1993;13:409-14.

 

160.  LAPIERRE, Y, BROWNE, M, OYEWUMI, K, SARANTIDIS, D

Alprazolam and amitriptyline in the treatment of moderate depression.  Int Clin Psychopharm 1994;9:41-45.

 

161.  RAVINDRAN, AV, BIALIK, B, LAPIERRE, Y

Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry 1994;39:2126.

 

162.  LAPIERRE, Y

Pharmacological therapy of dysthymia. Acta Psychiatr Scand 1994;89 (suppl 383):42-48.

 

163.  RAVINDRAN, AV, BIALIK, B, LAPIERRE, Y

Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: I. Platelet monoamine oxidase and the dexamethasone suppression test. J Affect Disord 1994;31:111-117.

 

164.  RAVINDRAN, AV, BIALIK, B, LAPIERRE, Y

Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: II. Urinary metabolites of serotonin, norepinephrine, epinephrine and melatonin. J Affect Disord 1994;31:119-123.

 

165.  BAKISH, D, RAVINDRAN, A, HOOPER, C, LAPIERRE, Y

 

Psychopharmacologic treatment response of patients with a DSM-III diagnosis of dysthymic disorder.  Psychopharm Bull 1994:30:53-59.

 

166.  RAVINDRAN, AV, CHUDZIK, J, BIALIK, B, LAPIERRE, Y, HRDINA, P

Platelet serotonin measures in primary dysthymia. Am J Psychiatry 1994:151:1369-71.

 

167.  LAPIERRE, YD

Schizophrenia and manic-depression:  separate illnesses or a continuum? Can J Psychiatry 1994;39(Suppl 2).

 

168.  HRDINA, P, BAKISH, D, CHUDZIK, J, RAVINDRAN, A, LAPIERRE, Y

Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiatry Neurosci 1995;20:11-19.

 

169.  FILTEAU, MJ, BARUCH, P, LAPIERRE, YD, BAKISH, D, BLANCHARD, A

SSRIs in anxious-agitated depression: post-hoc analysis of 279 patients. Int Clin Psychopharm 1995;10:51-54.

 

170.  BIALIK, RJ, RAVINDRAN, AV, BAKISH, D, LAPIERRE, YD

A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci 1995;20:265-270.

 

171.  LAPIERRE, Y, HAMILTON, DM

Placebo in clinical trials.  Ital J Psychiatry Neurobehav Sci 1994;4:73-79.

 

172.  LAPIERRE, Y, BENTKOVER, J, SCHAINBAUM, S, MANNERS, S.

Direct cost of depression: analysis of treatment costs of paroxetine vs. impramine in Canada. Can J Psychiatry 1995;40:370-377.

 

173.  LAPIERRE, Y

Placebo: A potent but misunderstood psychotrope [editorial].  J Psychiatry Neurosci 1995;20:173-174.

 

174.  KNOTT, V, TELNER, J, LAPIERRE, Y, BROWNE, M, HORN, E

Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord 1996;39:175-194.

 

175.  ADDINGTON, D, WILLIAMS, W, LAPIERRE, Y

Placebos in clinical trials of psychotropic medication [position paper]. Can J Psychiatry 1997;42(3).

 

176.  AWAD AG, LAPIERRE YD, ANGUS C, RYLANDER A, The Canadian Remoxipride Study Group

Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J Psychiatry Neurosci 1997;22:244-248.

 

177.  HRDINA, P, BAKISH, D, RAVINDRAN, A, CHUDZIK, J, CAVAZZONI, P, LAPIERRE, Y

Platelet serotonergic indices in major depression: up-regulation of 5-HT2a receptors unchanged by antidepressant treatment.  Psychiatr Res 1997;66:73-85.

 

178.  LAPIERRE, YD, JOFFE, R, MCKENNA, K, BLAND, R, KENNEDY, S, INGRAM, P, REESAL, R, RICKHI, BG, BEAUCLAIR, L, CHOUINARD, G, ANNABLE, L

Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. J Psychiatry Neurosci 1997;22:118-126.

 

179.  RAVINDRAN, AV, JONES, BW, AL-ZAID, K, LAPIERRE, YD

Effective treatment of mania with olanzapine: 2 case reports [letter]. J Psychiatry Neurosci 1997;22:345-346.

 

180.  RAVINDRAN, A, BIALIK, R, HRDINA, P, MERALI, Z, ANISMAN, H, LAPIERRE, Y

 

Neuroendocrine and anthropometric measures in major depression: the effect of antidepressant treatment. Hum Psychopharmacol Clin Exp 1997;12:583-589.

 

181.  LAPIERRE, YD

Ethics and placebo [editorial]. J Psychiatry Neurosci 1998;23:9-11.

 

182.  LAPIERRE, YD, SILVERSTONE, P, REESAL, RT, SAXENA, B, TURNER, P, BAKISH, D, PLAMONDON, J, VINCENT, PM, REMICK, RA, KROFT, C, PAYEUR, R, ROSALES, D, LAM, R, BOLOGA, M

A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. J Clin Psychopharm 1998;18(4):269-273.

 

183.  KANE, JM, AGUGLIA, E, ALTAMURA, AC, AYUSO GUTIERREZ, JL, BRUNELLO, N, FLEISCHHACKER, WW, GAEBEL, W, GERLACH, J, GUELFI, JD, KISSLING, W, LAPIERRE, YD, LINDSTROM E, MENDLEWICS, J, RACAGNI, G, CARULLA, LS, SCHOOLER, NR

Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66.

 

184.  LAPIERRE, YD, ANGUS, C, AWAD, AG, SAXENA, BM, JONES, B, WILLIAMSON, P, VINCENT, P, CARLE, R, LAVALLEE YJ, MANCHANDA, R, GAUTHIER B, WOLF, MA, TEEHAN, MD, DENIS, JF, MALLA, AK, OYEWUMI, LK, BUSSE, E, LABELLE, A, CLAESSON, L, GRAFFORD, K

The treatment of negative symptoms: a clinical and methodological study. Int Clin Psychopharm 1999;14:101-112.

 

185.  RAVINDRAN, AV, LAPIERRE, YD, ANISMAN, H

Obsessive-compulsive spectrum disorders: effective treatment with paroxetine. Can J Psychiatry 1999oct:44(8) 805-7

 

186.  DU, L, FALUDI, G, PALKOVITS, M, DEMETER, E, BAKISH, D, LAPIERRE, YD, SOTONYI, P, HRDINA, PD

Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry 1999;46:196-201.

 

 

187.  OWEN, D, DU, L, BAKISH, D, LAPIERRE, YD, HRDINA, PD

Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res 1999;87:1-5.

 

1.         LABELLE, A, BOULAY, LJ, LAPIERRE, YD

Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. Can J Psychiatry 1999;44:887-892.

 

189.  DU, L, BAKISH, D, RAVINDRAN, AV, LAPIERRE, YD, HRDINA, PD

Association of polymorphism of serotonin2A receptor with suicidal ideation in major depression. Am J Med Genet-Neuropsychiatric Genetics

96:56-60,2000

 

190.LAPIERRE YD, ANGUS C AWAD AG, SAXENA BM, JONES B, WILLIAMSON P, VINCENT P, CARLE R, MANCHANDA R, GAUTHIER MA, WOLF MD,  TEEHAN JF, DENIS JF, MALLA AK, OYEWUMI LK, BUSSE E, LABELLEA, CLAESSON Y, GRAFFORD K.

Tratamiento de los sintomas negativos: un estudio clinico y metodologico-Revista de Toxicomanias No 26-primer trimester-   2001;31-46.(reproduced from Int. Clin. Psychopharm.)

 

 

ORIGINAL PAPERS IN NON-REFEREED JOURNALS

 

1-LAPIERRE, Y et al

Report of the Expert Advisory Committee on the use of drugs in the treatment of abuse and dependence to narcotic and controlled drugs.  Med Assoc J 1990;143(9):861-865.

 

2-LAPIERRE, Y

Update on the use of antidepressants.  Ontario Medicine Special Focus on Psychiatry, 1992.

 

 

 

3-RAVINDRAN, AV, LAPIERRE, YD

Advances in the diagnosis and treatment of dysthymia.  Int Psychiatry Today 1993;3:31-11.

 

4-LAPIERRE, Y, HAMILTON, DM

Anxiety and depression: distinct or a continuum?  Focus on Depression and Anxiety  1993 (Nov).

 

5-LAPIERRE, Y

The importance of sleep in treatment of depression.  Current Trends in Psychiatric Medicine 1995:2:1.

 

6-LAPIERRE, Y

Pro: Placebo in psychiatric research. Communiqué (NCEHR) 1998;8(2):11-13.

 

 

BOOK AND MONOGRAPH CHAPTERS

 

1.     DICK, P, MORMONT, C, DUFOUR, H, HUBER, JP, LUCCIONI, H, PRINGUEY, D, MOMBOUR, W et al.

Le manuel AMDP (Système de documentation et d'évaluation de la psychopathologie). Liège: Presses universitaires de Liège; 1978 (1st ed); 1981 (2nd ed).

 

2.     LAPIERRE, Y

Pharmacologie clinique basée sur la thérapeutique. Paris: Expansion scientifique française; 1979 (1st ed) pp 1709-1719; 1988 (2nd ed) pp 1274-81.

 

3.     RASTOGI, RB, LAPIERRE, Y, SINGHAL, RL, NAIR, NPV

Evidence for involvement of dopamine in the action of diazepam: potentiation of haloperidol and chlorpromazine actions in the brain. In: Advanced Biochemical Psychopharmacology: Long-term effects of neuroleptics, Volume 24. New York: Raven Press; 1980. pp 283-289.

 

4.     LAPIERRE, Y, KNOTT, V

Psychophysiological correlates of mental disorders. In: Neuroendocrine Regulation and Altered Behaviour. London (UK): Croom-Helm Ltd; 1981. pp 317-334.

 

5.     LAPIERRE, Y, OYEWUMI, LK

Psychiatric adverse effects of psychotherapeutic drugs. In: Physical Illness in Psychiatric Patients. Springfield (IL): Charles Thomas Publishers; 1982. pp 101-118.

 

6.     ANISMAN, H, LAPIERRE, Y

Neurochemical aspects of stress and depression: formulation and caveats. In: Neufeld R, editor. Psychological Stress and Psychopathology. New York: McGraw Hill; 1982. pp 179-217.

 

7.     OYEWUMI, LK, LAPIERRE, Y

Thioxanthenes: measurements, kinetics and clinical response. Elsevier; 1985. pp 115-128.

 

8.     LAPIERRE, Y, TELNER, J

Pharmacological approaches to mania. In: Pharmacotherapy of Affective Disorders. London (UK): Croom Helm; 1985. pp 312-327.

 

9.     LAPIERRE, Y

Present status and future of outpatient drug management of schizophrenia. Outpatient psychiatry progress, treatment, prevention. Psychiatric Outpatient Centers of America; 1985. pp 196-205.

 

 

 

10.   LAPIERRE, Y, REESAL, R

Pharmacological management of aggressivity and self-mutilation in the mentally retarded. Psychiatric Clinics of North America; 1986. pp 745-754.

 

11.   LAPIERRE, Y

New approaches to the pharmacology treatment of anxiety and depression. Anxiety Disorders Psychological & Biological Perspectives. New York: Plenum Press; 1986. pp 215-228.

 

12.   LAPIERRE, Y, RAVAL, K

Pharmacotherapy of affective disorders in children and adolescents.  In: Affective Disorders and Anxiety in the Child & Adolescent. Series on Psychiatric Clinics of North America, 12(4); 1989. pp 951-61.

 

13.   LAPIERRE, Y

Lithium et normothymiques. In: Médicaments en neurologie & psychiatrie. Paris; 1990. pp 72-83.

 

14.   LAPIERRE, Y

Les psychostimulants. In: Médicaments en neurologie & psychiatrie. Paris; 1990. pp 84-89.

 

15.   LAPIERRE, Y

Epidemiology, diagnosis and treatment of panic disorder. Excerpta Medica 1991.

 

16.   LAPIERRE, Y

Conclusion to Les IMAO: Les Grands Médicaments series. Paris: Les Éditions Marketing Ellipse; 1993. pp 119-26.

 

17.   GROF, P, AKHTER, MI, CAMPBELL, M, GOTTFRIES, CG, KHAN, I, LAPIERRE, Y, LEMBERGER, L et al

Clinical evaluation of psychotropic drugs for psychiatric disorders: principles and proposed guidelines. World Health Organization Expert Series on Biological Psychiatry, Vol. 2. Hogrefe & Huber; 1993.  202 pp.

 

18.   LAPIERRE, Y, MUNRO, A, BRADWEJN, J, REESAL, R

Depression: scope of the problem. In: The role of sertraline in the treatment of depression. Montreal: PharmaLibri; 1993. pp 3-8.

 

19.   LAPIERRE, Y, JONES, B

Drug treatment of negative schizophrenic symptoms. In: Shriqui CL, Nasrallah HA, editors. Contemporary Issues in the Treatment of Schizophrenia. Washington (DC): American Psychiatric Press Inc; 1995.

 

20.   LAPIERRE, Y

Funding in clinical trials. In: Rae-Grant Q, editor.  Images in Psychiatry. Washington (DC): American Psychiatric Press; 1996.

 

21.   RAVINDRAN, AV, LAPIERRE YD

Primary dysthymia: predictors of treatment response. In: Akiskal HS, Cassano GB, editors. Dysthymia and the Spectrum of Chronic Depressions. New York: The Guilford Press; 1997. pp 44-53.

 

22.   LABELLE, A, LAPIERRE, YD, JONES, BD

MTraitements biologiques : antipsychotiques (chapter 43).  In: Psychiatrie clinique : approche bio-psycho-sociale. 3rd edition.  Montreal: Gaëtan Morin Éditeur; 2001

 

23.   LAPIERRE YD, BAKISH, D, HOOPER, CL

Pharmacological validity of diagnostic separation.  In: Montgomery S, Halbreich U (editors). Pharmacotherapy of Mood and Cognition. Washington (DC): American Psychiatric Press; 1999. Forthcoming.

 

Yvon Lapierre

May 5,2016